Prof. Beka Solomon

Education:

1959-1964 B.Sc. Polytechnic Institute, Iassy, Romania, Chemical Engineering

M.Sc. Polytechnic Institute, Iassy, Romania, Chemical Engineering

1972-1976 PhD. Weizmann Institute of Science, Rehovot, Israel, Biophysics & Biochemistry

 

Academic and Professional Experience:

1979-1985 Investigator, Department of Molecular Microbiology and Biotechnology, Tel Aviv University

1985-1989 Senior investigator, Department of Molecular Microbiology and Biotechnology, Tel Aviv University

1987-1988 Visiting Lecturer, Center for Biophysics and Biochemistry, Harvard Medical School, Boston, Ma., USA & Brigham and Women's Hospital, Boston, Ma. USA

1989 - 1996 Senior lecturer, Department of Molecular Microbiology and Biotechnology, Tel Aviv University

1996 - 2002 Associate Professor, Department of Molecular Microbiology and Biotechnology, Tel Aviv University

2002-present Full Professor, Department of Molecular Microbiology and Biotechnology, Tel Aviv University

2002 Tel-Aviv University, Incumbent of the Chair for Biotechnology of Neurodegenerative Diseases

2007 Selected by Scientific American for their list of The 50 Leading Scientists in the World for 2007.

 

My scientific interest is focused on investigation of biorecognition in general and on the nature of the interactions of antibodies and their corresponding antigens in particular. In my research work I am involved in the elucidation of the mode of action of monoclonal antibodies (mAbs) on the structure and function of their corresponding antigens in in vitro and in vivo environments. Antibodies were found to act as reporting probes for the detection of conformational changes induced in various protein antigens by environmental factors, as well as playing active roles in inducing changes and rearrangements in the antigen molecule. The following topics are being investigated:

1. detection of conformation changes in the protein antigen by their mAbs.
2. stabilization of the antigen structure by mAbs.
3. Chaperone characteristics of mAbs leading to the refolding of the respective antigen.
4. Prevention of aggregation and solubilization of previously formed protein aggregates.

 

In addition, I am involved in the design and production of novel antibodies with the desired combination of binding specificity and biological properties.

 

For a full research description (pdf)

 

Books

1. Solomon, B., Taraboulos, A. and Katchalski-Katzir, E. Conformational Diseases. Amyloid: Int. J. Exp. Clin. Invest. 6 (1999) 225-228.

 

 

Articles

Solomon B. Generation of anti-beta amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. Vaccine (2005) 18:2327-30.

 

Arbel M, Yacobi I, Solomon B. Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci USA (2005) 10:102(21):7718-23.

 

Solomon, B. Peptide vaccine for Alzheimer's disease. Handbook of Biologically Active Peptides (2005) 535-540.

 

Solomon, B. In vivo targeting of amyloid plaques via intranasal administration of phage anti-β-amyloid antibodies. Proceedings of ADPD Conference 2005.
 

Rebe S. and Solomon B. Deglycosylation of anti-β amyloid antibodies inhibit microglia activation in bv-2 cellular model. American Journal of Alzheimer's and Related Diseases. (2005) 20(5):303-13.

 

Solomon B. Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination. J. Alzheimer's Dis. (2006)1387-2877, 9: (3, Supplement), 433-438.

 

Orgad, S., Goldfinger N., Cohen, G., Rotter, V., Solomon, B. Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein. FEBS Lett. Oct 24;579(25):5609-15 (2005).

 

Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J. Neurosci. Res. (2006) 84(2):434-43.

 

Rakover I., Arbel M. and Solomon B. APP β-site-specific antibody improves cognitive function and reduces microhemmorhage and neuroinflammation in Tg 2576 mice without affecting brain Aβ levels. Neurodegen Dis (2007) 4(5):392-402.

 

Becker M., Lavie V. and Solomon B. Stimulation of endogenous neurogenesis by anti-EFRH immunization in transgenic mice model of Alzheimer’s disease. Proc Natl Acad Sci USA (2007) 104(5):1691-6.

 

Solomon B. Active Immunization against Alzheimer's beta-amyloid peptide using phage display technology. Vaccine (2007) 25(16):3053-6.

 

B. Solomon. Immunological approaches for amyloid beta clearance toward Alzheimer's disease treatment. Rejuvenation Research. (2007). In Press.

 

 

Chapters in Books

Solomon, B., Larsen, K.S. and Riordan, J.F. A neo isoform of Carboxypeptidase A produced by a single proteolytic cleavage. Ann. N.Y. Acad. of Sc. 613, (1990) 594 600.

 

B. Solomon and G. Fleminger. Application of Highly Active Matrix Conjugated Monoclonal Antibodies for the Isolation and Analysis of Enzymes, Monoclonal Antibodies. Applications in Clinical Oncology. (Chapman and Hall, eds.) England, Chap. 20, (1991) 193 201.

 

Solomon, B., Schwartz, F. and Levi, A. Dot enzyme linked immunoassay of urine albumin. Progress in Clin. Biochem.( K. Miyai, T. Tanno and E. Ishikawa, eds.) (1992) 247 249.

 

Solomon, B. and Goldstein, L. Modulation of the catalytic pathway of carboxypeptidase A by conjugation with polyvinylalcohols.
Advances in Molecular and Cell Biology (E. E. Bittar, B. Danielsson and L. Bulow, eds.) (1996) 15A, 33-45.

 

Solomon, B. and Goldstein, L. Modulation of the catalytic pathway of carboxypeptidase A by conjugation with polyvinylalcohols. Advances in
Molecular and Cell Biology (E. E. Bittar, B. Danielsson and L. Bulow, eds.) (1996) 15A, 33-45.

 

Solomon, B., Hanan, E., Koppel, R., Frankel, D., Ophir, I. and Schenck, D.
The amino terminus of the -amyloid peptide contains an essential epitope for maintaining its solubility. In Progress in Alzheimer’s and Parkinson’s Diseases. 49 (1998) 201-213 (Eds. A. Fisher, I. Hanin, M. Yoshida).

 

Solomon, B., Gozanski-Katzav,T., Koppel, R. and Hanan-Aharon, E. Activity of monclonal antibodies in prevention of in vitro aggregation of their antigens. Stability and Stabilization of Biocatalysts. ( A. Ballesteros, F.J. Plou, J.L. Iborra and P.J. Halling, eds.) 183 (1998) 183-188.

 

Solomon, B. and Frenkel, D. Generation of autoantibodies towards Alzheimer’s disease vaccination. In Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics. (ed. K. Iqbal). (2001) 769-775.

 

Solomon, B. Aluminium, Calmodulin and Alzheimer’s Disease. Aluminium in Alzheimer’s Disease.Elsevier (Ed. C. Exley). (2001) 393-409.

 

Solomon, B. and Frenkel, D. Fast induction of anti-β-amyloid peptide immune response. Research and Practice in Alzheimer’s Disease and Other Dementias 5 (2001) 27-31.

 

Solomon, B. Therapeutic antibodies, a new approach for treatment of Alzheimer’s disease. Conformational Diseases (Eds. B. Solomon, A. Taraboulos, E. Katzir). (2001) 276-281.

 

Solomon, B. Towards Diagnosis and Treatment of Alzheimer’s Disease. Research and Perspectives in Alzheimer’s Disease. Fondation IPSEN (Eds. K. Beyreuther, Y. Christen, C.L. Masters) (2003) 11-19.
 

Solomon, B. Peptide vaccine for Alzheimer's disease. Handbook of Biologically Active Peptides (2005) 535-540.

 

Solomon, B. In vivo targeting of amyloid plaques via intranasal administration of phage anti-β-amyloid antibodies. Proceedings of ADPD Conference (2005).
 

Solomon, B. Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination. Alzheimer Anniversary Issue (2005).

 

Alzheimer’s Disease: New Advances: Collection of Selected Articles of Papers Presented at the 10th International Conference on Alzheimer’s Disease and Related Disorders. Editors Khalid Iqbal, Bengt Winblad, Jesus Avila, Madrid, Spain, July 15-20, 2006.

 

 

Patents

Z. Hollander, B. Solomon and E. Katchalski Katzir
"Reagent for the Assay of Enzymes (and Isoenzymes) in Clinical Systems using Monoclonal Antibodies"

Israel Patent No. 75828 (1985)

U.S. Patent No. 52692/1988

Japanese Patent No. 165708/1986

German Patent No. 3623845.5/87

 

 

B. Solomon, G. Fleminger and E. Hadas
"Immobilization of Monoclonal Antibodies on Eupergit C and its Derivatives"

German Patent No. P 373872 1.9/87

U.S. Patent No.4 948836/90

Filed also in Denmark, France, United Kingdom, Israel, The Netherlands, Sweden, and Switzerland

 

B. Solomon
"Prevention of protein aggregation"
U.S. Patent PCT/US94/16092. 1997.

 

E. Paley and B. Solomon
“Diagnostic test of Alzheimer’s disease”

Patent application 1999.

 

D. Govorko, G. Cohen and B. Solomon
“Construction of a single-chain antibody (scFv) against the conserved epitope of mutant p53 protein in human tumors and its application for cancer therapy”.

Patent application 1999.

 

D. Frenkel and B. Solomon
“Therapeutic antibodies against Alzheimer’s disease via EFRH immunization.”

Patent application, 1999.

 

E. Hanan and B. Solomon
“Immunomodulation of prion toxicity.”

Patent application 2000.